Ana Maestre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ana Maestre has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Javier Gallego
Internal Medicine Department. Hospital General Universitario de Elche, Spain
2 shared publicationsManuel Monreal
UCAM Univ Catolica San Antonio Murcia, Fac Hlth Sci, Chair Study Thromboembol Dis, Madrid, Spain
2 shared publicationsVicente Gil
Universidad Miguel Hernández, Spain
2 shared publicationsA. Gonzálvez Gasch
Servicio de Medicina Interna, Hospital Collado Villalba, Madrid, España
1 shared publicationAlberto Martín-Hidalgo
Internal Medicine Department. Hospital General Universitario de Elche, Spain
1 shared publicationAlberto Martín‐Hidalgo
Head of Department, Internal Medicine Department, Hospital General Universitario de Elche, Elche, Spain
1 shared publication
Latest Publications
- 13 September 2024
- Published by Elsevier in Thrombosis Research
- Vol. 243, 109153
Predicting intracranial bleeding during anticoagulation for venous thromboembolism within different time frames: Findings from the RIETE registry
- 13 September 2024
- Published by Elsevier in Thrombosis Research
- Vol. 243, 109153
Predicting intracranial bleeding during anticoagulation for venous thromboembolism within different time frames: Findings from the RIETE registry
- Open Access
- 24 April 2023
- Published by Sociedad Espanola de Medicina Interna (SEMI) in Revista Española de Casos Clínicos en Medicina Interna
- Vol. 8 (1) , 39-42
Lo que el prurito esconde
El prurito es un síntoma frecuente pero inespecífico que puede presentarse en multitud de patologías. A través de este caso clínico veremos como este síntoma nos permite llegar al diagnóstico de una entidad hematológica rara y de mal pronóstico.
- 24 April 2023
- Published by Sociedad Espanola de Medicina Interna (SEMI) in Revista Española de Casos Clínicos en Medicina Interna
- Vol. 8 (1) , 39-42
Open AccessLo que el prurito esconde
El prurito es un síntoma frecuente pero inespecífico que puede presentarse en multitud de patologías. A través de este caso clínico veremos como este síntoma nos permite llegar al diagnóstico de una entidad hematológica rara y de mal pronóstico.
- Open Access
- 24 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5632
Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia. PROTHROMCOVID is a randomized, unblinded, controlled, multicenter trial enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia. Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) groups. All tinzaparin doses were administered once daily during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge. The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days. Of the 311 subjects randomized, 300 were included in the prespecified interim analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]). The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (p = 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Due to these results and the futility analysis, the trial was stopped. In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to affect the risk of thrombotic event, non-invasive ventilation, or mechanical ventilation or death. Trial Registration ClinicalTrials.gov Identifier (NCT04730856). Edura-CT registration number: 2020-004279-42.
- 24 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5632
Open AccessEfficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia. PROTHROMCOVID is a randomized, unblinded, controlled, multicenter trial enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia. Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) groups. All tinzaparin doses were administered once daily during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge. The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days. Of the 311 subjects randomized, 300 were included in the prespecified interim analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]). The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (p = 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Due to these results and the futility analysis, the trial was stopped. In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to affect the risk of thrombotic event, non-invasive ventilation, or mechanical ventilation or death. Trial Registration ClinicalTrials.gov Identifier (NCT04730856). Edura-CT registration number: 2020-004279-42.
- 27 March 2022
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (7) , e13774
Major bleeding in patients with pulmonary embolism presenting with syncope
Introduction: Syncope has been shown to be a risk factor of bleeding in patients receiving thrombolytic therapy for acute pulmonary embolism (PE). Whether syncope predicts bleeding in a broader population of patients with PE remains unknown.Methods: We used the RIETE registry data to assess whether initial presentation with syncope could predict bleeding in PE patients receiving anticoagulant therapy, and to explore the association between presence of syncope and timing and site of major bleeding events.Results: Among 45,765 patients with acute PE from March 2001 to January 2021, 6760 (14.8%) had syncope. Patients with syncope were older and more likely to have hypotension, tachycardia, hypoxaemia or elevated troponin levels than those without syncope. They also were more likely to receive thrombolytics. During the first 90 days, 1097 patients (2.4%) suffered major bleeding (gastrointestinal 335, hematoma 271 and intracranial 163) and 3611 died (158 had fatal bleeding). Patients with syncope had a higher rate of major bleeding (odds ratio [OR]: 1.63; 95% CI: 1.41–1.89) and a nonsignificantly higher rate of fatal bleeding (OR: 1.47; 95% CI: 0.99–2.17) than those without syncope. Multivariable analysis confirmed that patients with syncope were at increased risk for major bleeding (adjusted hazard ratio [aHR]: 1.34; 95% CI: 1.15–1.55). On sensitivity analysis, the increased risk for major bleeding was confirmed in patients initially receiving anticoagulant therapy without thrombolytics at 7 days (aHR: 1.47; 95% CI: 1.13–1.91) and 90 days (aHR: 1.33; 95%CI: 1.13–1.56).Discussion: Syncope is a predictor of major bleeding events in patients with PE, even among those receiving anticoagulation monotherapy.
- 27 March 2022
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (7) , e13774
Major bleeding in patients with pulmonary embolism presenting with syncope
Introduction: Syncope has been shown to be a risk factor of bleeding in patients receiving thrombolytic therapy for acute pulmonary embolism (PE). Whether syncope predicts bleeding in a broader population of patients with PE remains unknown.Methods: We used the RIETE registry data to assess whether initial presentation with syncope could predict bleeding in PE patients receiving anticoagulant therapy, and to explore the association between presence of syncope and timing and site of major bleeding events.Results: Among 45,765 patients with acute PE from March 2001 to January 2021, 6760 (14.8%) had syncope. Patients with syncope were older and more likely to have hypotension, tachycardia, hypoxaemia or elevated troponin levels than those without syncope. They also were more likely to receive thrombolytics. During the first 90 days, 1097 patients (2.4%) suffered major bleeding (gastrointestinal 335, hematoma 271 and intracranial 163) and 3611 died (158 had fatal bleeding). Patients with syncope had a higher rate of major bleeding (odds ratio [OR]: 1.63; 95% CI: 1.41–1.89) and a nonsignificantly higher rate of fatal bleeding (OR: 1.47; 95% CI: 0.99–2.17) than those without syncope. Multivariable analysis confirmed that patients with syncope were at increased risk for major bleeding (adjusted hazard ratio [aHR]: 1.34; 95% CI: 1.15–1.55). On sensitivity analysis, the increased risk for major bleeding was confirmed in patients initially receiving anticoagulant therapy without thrombolytics at 7 days (aHR: 1.47; 95% CI: 1.13–1.91) and 90 days (aHR: 1.33; 95%CI: 1.13–1.56).Discussion: Syncope is a predictor of major bleeding events in patients with PE, even among those receiving anticoagulation monotherapy.
- 1 August 2017
- Published by Elsevier in Revista Clínica Española
- Vol. 217 (6) , 342-350
Actualización en la estratificación de riesgo del tromboembolismo pulmonar agudo sintomático
- 1 August 2017
- Published by Elsevier in Revista Clínica Española
- Vol. 217 (6) , 342-350
Actualización en la estratificación de riesgo del tromboembolismo pulmonar agudo sintomático
- 31 May 2009
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 20 (3) , 313-318
Prediction clinical profile to distinguish between systolic and diastolic heart failure in hospitalized patients
- 31 May 2009
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 20 (3) , 313-318
Prediction clinical profile to distinguish between systolic and diastolic heart failure in hospitalized patients
- 12 February 2009
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 15 (1) , 55-61
Diagnostic accuracy of clinical criteria for identifying systolic and diastolic heart failure: cross‐sectional study
Objective To determine the validity and clinical usefulness of clinical criteria in the diagnosis of systolic and diastolic heart failure.Design Cross‐sectional diagnostic study.Methods 216 patients admitted consecutively to the cardiology section of an academic hospital with a suspected diagnosis of heart failure in a period of 12 months. A definite diagnosis of heart failure (echocardiographic diagnostic criteria of left ventricular dysfunction) was cross‐matched with the results obtained using the test under investigation (Framingham clinical diagnostic criteria for heart failure). Sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio for positive test result (LR+) and likelihood ratio for negative test result (LR−) were calculated and used to construct clinical decision‐making diagrams.Results The Framingham clinical criteria are very sensitive (92%) and moderately specific (79%). The diagnosis of heart failure was ruled out with a good LR− (0.1) but the diagnosis was confirmed with only a low level of evidence as the LR+ was 4.3. The main difference found between systolic and diastolic heart failure is that in the case of systolic failure the disease is ruled out conclusively (0.04), whereas in the case of diastolic failure the change in probability generated is at the borderline between conclusive and moderate (0.1).Conclusion The absence of the Framingham clinical criteria rules out the diagnosis of heart failure, particularly in the case of systolic heart failure. However, the presence of these criteria do not necessarily confirm the diagnosis, which may be based in echocardiography.
- 12 February 2009
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 15 (1) , 55-61
Diagnostic accuracy of clinical criteria for identifying systolic and diastolic heart failure: cross‐sectional study
Objective To determine the validity and clinical usefulness of clinical criteria in the diagnosis of systolic and diastolic heart failure.Design Cross‐sectional diagnostic study.Methods 216 patients admitted consecutively to the cardiology section of an academic hospital with a suspected diagnosis of heart failure in a period of 12 months. A definite diagnosis of heart failure (echocardiographic diagnostic criteria of left ventricular dysfunction) was cross‐matched with the results obtained using the test under investigation (Framingham clinical diagnostic criteria for heart failure). Sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio for positive test result (LR+) and likelihood ratio for negative test result (LR−) were calculated and used to construct clinical decision‐making diagrams.Results The Framingham clinical criteria are very sensitive (92%) and moderately specific (79%). The diagnosis of heart failure was ruled out with a good LR− (0.1) but the diagnosis was confirmed with only a low level of evidence as the LR+ was 4.3. The main difference found between systolic and diastolic heart failure is that in the case of systolic failure the disease is ruled out conclusively (0.04), whereas in the case of diastolic failure the change in probability generated is at the borderline between conclusive and moderate (0.1).Conclusion The absence of the Framingham clinical criteria rules out the diagnosis of heart failure, particularly in the case of systolic heart failure. However, the presence of these criteria do not necessarily confirm the diagnosis, which may be based in echocardiography.